ALXO: Lead assets advance toward phase III, with strong biomarker focus and robust financial runway
Two lead programs are advancing toward pivotal studies, with evorpacept showing strong biomarker-driven efficacy and ALX2004 progressing through dose escalation in multiple tumor types. Financial runway supports operations through mid-2028, and companion diagnostic development is ongoing.Based on A…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.